Trial Pack For Selective NSAID

Practitioners can now trial the first COX-2 specific NSAID for horses, Equioxx® (firocoxib) with a limited special offer trial pack containing 10 tubes of the oral paste. EQUIOXX is the only equine NSAID that is highly COX-2 selective, acting to reduce pain and inflammation whilst preserving the natural physiological effects of the COX-1 enzyme, at therapeutic levels. In fact EQUIOXX is up to 643 times more selective for COX-2 than COX-1. Field studies have confirmed that firocoxib is highly effective at controlling pain and improving function in horses with chronic osteoarthritis. Jim Tipp BVSc MRCVS, partner at Shropshire based Fyrnwy Equine Clinics says that having a firocoxib licensed for horses provides some useful options: “As a COX-2 specific NSAID it is not only a good analgesic, but is also an excellent anti-inflammatory. “In addition, the COX-1 sparing properties of Equioxx are beneficial where there is increased risk of ulceration,” he adds. EQUIOXX is also available as a low dose injectable solution. For more information contact Merial Customer Services on 0870 6000 123.

More from

• Animus launches SkinBond Multi for enhanced wound care
• IVC Evidensia reports 82% cut in Farm antibiotic use and 20% carbon emissions reduction
• Vet professionals flock to sign up to transformative locum platform
• The ProSalus Foundation launches urgent appeal for UK vets to support Ukrainian colleagues
• Vetsure Named Business of the Year at 2025 SME National Business Awards